Clinical Trials

Showing trials with last updates posted in 2026.

NCT06770582 | RECRUITING | PHASE2
160 participants

Testing the Addition of the Immunotherapy Drug, Pembrolizumab, to Radiation Therapy Compared to the Usual Chemotherapy Treatment During Radiation Therapy for Bladder Cancer, PARRC Trial

Study Type:
INTERVENTIONAL
Last Updated:
2026-08-24
Start Date:
2025-06-03
Completion:
2032-02-01
Conditions
  • Non-Muscle Invasive Bladder Urothelial Carcinoma
  • Recurrent Non-Muscle Invasive Bladder Urothelial Carcinoma
  • Stage I Bladder Cancer AJCC v8
Interventions
  • PROCEDURE
  • DRUG
  • BIOLOGICAL
  • OTHER
  • RADIATION
No Results Yet
NCT06664502 | COMPLETED | PHASE1/PHASE2
38 participants

A 2-part Study Consisting of a Multiple Ascending Dose Safety Study in Participants With Macular Edema Following Branch Retinal Vein Occlusion and a Dose-finding Safety and Preliminary Efficacy Study in Participants With Either Diabetic Macular Edema or Neovascular Age-related Macular Degeneration

Study Type:
INTERVENTIONAL
Last Updated:
2026-08-24
Start Date:
2024-11-12
Completion:
2026-03-25
Conditions
  • Diabetic Macular Edema (DME)
  • Neovascular Age-related Macular Degeneration (NVAMD)
  • BRVO - Branch Retinal Vein Occlusion
Interventions
  • DRUG
No Results Yet
NCT06620302 | SUSPENDED | PHASE1/PHASE2
81 participants

Testing the Addition of an Anti-cancer Drug, DT2216, to the Usual Chemotherapy Treatment for Relapsed or Refractory Solid Tumors and Fibrolamellar Carcinoma

Study Type:
INTERVENTIONAL
Last Updated:
2026-08-24
Start Date:
2025-06-12
Completion:
2031-12-30
Conditions
  • Childhood Fibrolamellar Carcinoma
  • Recurrent Childhood Fibrolamellar Carcinoma
  • Recurrent Childhood Malignant Solid Neoplasm
  • Recurrent Fibrolamellar Carcinoma
  • Recurrent Malignant Solid Neoplasm
  • Refractory Childhood Fibrolamellar Carcinoma
  • Refractory Childhood Malignant Solid Neoplasm
  • Refractory Fibrolamellar Carcinoma
  • Refractory Malignant Solid Neoplasm
Interventions
  • BIOLOGICAL
  • PROCEDURE
  • DRUG
No Results Yet
NCT06590857 | ACTIVE_NOT_RECRUITING | PHASE1/PHASE2
16 participants

Trial of 225Ac-DOTATATE (RYZ101) in Subjects With ER+, HER2-negative Unresectable or Metastatic Breast Cancer Expressing SSTRs.

Study Type:
INTERVENTIONAL
Last Updated:
2026-08-24
Start Date:
2024-07-19
Completion:
2028-10-31
Conditions
  • Metastatic Breast Cancer
  • HER2-negative Breast Cancer
  • ER+ Breast Cancer
  • Advanced Breast Cancer
  • Metastatic Breast Cancer With Bone Involvement
  • Bone Metastases in Subjects With Advanced Breast Cancer
  • ER-Positive HER2-Negative Breast Cancer
  • Estrogen Receptor-positive Breast Cancer
  • Hormone-sensitive Metastatic Breast Cancer
  • Hormone-Sensitive Breast Cancer
Interventions
  • DRUG
No Results Yet
Previous
Sorted by latest updates
Next
Showing 40 trials per page